Clinical Edge Journal Scan

Early emollient application: An effective strategy for atopic dermatitis prevention in infants


 

Key clinical point: Early application of emollients can effectively prevent atopic dermatitis (AD) in infants, with emollient emulsion seeming an optimal treatment option in infancy compared with creams or mixed emollients.

Major finding: The incidence of AD was significantly lower in high-risk infants receiving early emollients vs standard care (risk ratio 0.64; 95% CI 0.47-0.88), with surface under the cumulative ranking curve analysis revealing emollient emulsion (82.6%) as the optimal treatment for AD prevention in infants, followed by mixed emollient (77.4%) and emollient cream (21.9%).

Study details: This was a systematic review and network meta-analysis of 11 randomized controlled trials including 3483 infants without AD who received either prophylactic emollients (cream, emulsion, or mixed types) or standard care.

Disclosures: This study was supported by the Key Research and Development Project of Xinjiang Uygur Autonomous Region, China. The authors declared no conflicts of interest.

Source: Liang J, Hu F et al. Systematic review and network meta‐analysis of different types of emollient for the prevention of atopic dermatitis in infants. J Eur Acad Dermatol Venereol. 2022 (Nov 23). Doi: 10.1111/jdv.18688

Recommended Reading

Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis: Military Considerations
MDedge Dermatology
Saururus chinensis
MDedge Dermatology
Pooled safety data analysis of tralokinumab reported
MDedge Dermatology
Parental atopic dermatitis, asthma linked to risk of AD in offspring
MDedge Dermatology
Dupilumab significantly improves markers of AD severity in pediatric patients
MDedge Dermatology
Rocatinlimab shows promise in moderate-to-severe atopic dermatitis
MDedge Dermatology
Meta-analysis supports safe use of topical calcineurin inhibitors in AD
MDedge Dermatology
Tralokinumab improves microbial dysbiosis in lesional skin in AD
MDedge Dermatology
Tralokinumab improves microbial dysbiosis in lesional skin in AD
MDedge Dermatology
Phase 3 studies confirm long-term disease control with ruxolitinib cream in atopic dermatitis
MDedge Dermatology